EMA vs. Russia [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-09-20 21:21 (4667 d 01:06 ago) – Posting: # 11535
Views: 32,570

Hi mittyri,

❝ could you explain this disrepancy?


Yes. Russia’s GL is somewhat “closer” to the clinical situation (which was also the case in the EU in the past), whereas EMA concentrates on in vivo release (aka human test tubes). Keeping that in mind that an – even inactive pro-drug – is more sensitive to detect potential differences between formulations than any metabolite (especially of the rate of absorption).
BTW, I like Russia’s approach more, but I’m a dinosaur.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
341 visitors (0 registered, 341 guests [including 20 identified bots]).
Forum time: 22:27 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5